|
Post by mindovermatter on Jan 21, 2016 10:26:07 GMT -5
One thing to keep in mind is that this deal seems to encompass EVERYTHING Mannkind is working on and not just one indication. While it would be nice to know who is behind Receptor, we might just be seeing the tip of a very big iceberg ( a good kind and not the kind that sunk the Titanic.) Like every other snippet of news we've received over the years that hid some magical pot of gold that never materialized? There's no iceberg other than the insolvency one were headed towards. There is no magic associated with this deal. Hard to judge regarding how helpful because we know nothing about the prospects of getting any of the milestones when we need them. I hear ya. It is why I used the workd MIGHT. In no way am I saying this is a slam dunk deal.
|
|
|
Post by mindovermatter on Jan 21, 2016 10:12:40 GMT -5
Single-digit/low double-digit royalty deals comprise the majority of biotech agreements today. MannKind would pay NONE of the development, production and eventual marketing expenses whatsoever. These deals can still be quite lucrative and there are plenty of examples in the market today. good points. now that this is out of the way, the next fire to put out is how Mannkind can raise much needed cash unless Receptor Life is part of a plan to take MNKD private.
|
|
|
Post by mindovermatter on Jan 21, 2016 10:10:32 GMT -5
For the sake of the prior baseball analogies that were posted here; no it's not the homerun many here are yearning for but I'll take this sweet little single to start the rally.... P.S. Stevil...depends on what the ~10% is based off of ...right? :-) as an optimist I'm thinking it must be 5-10 percent of more than you may be thinking. ..just my guess. ;-) right, it's slow roller up the third base line and we are seeing if Mannkind is fast enough to run to first before the third baseman can bare hand it and throw Mannkind out. TBD.
|
|
|
Post by mindovermatter on Jan 21, 2016 10:06:20 GMT -5
In short, this is a start. Gets the momentum rolling. But it's not going to sustain the company and we need much more than this in the future if we hope to stay in business. That's the crux - it's a start, and we needed to start somewhere. Right now I'll take any positive news and trust that there will be more collaborations to follow. One thing to keep in mind is that this deal seems to encompass EVERYTHING Mannkind is working on and not just one indication. While it would be nice to know who is behind Receptor, we might just be seeing the tip of a very big iceberg ( a good kind and not the kind that sunk the Titanic.)
|
|
|
Post by mindovermatter on Jan 21, 2016 9:54:07 GMT -5
We really have no idea of what capabilities or competitive advantages RLS has and why MNKD picks this firm. We also do not know who is behind RLS and what track records they have to rest MNKD assure they are the good partner. As the saying goes, Beggars can't be choosers.
|
|
|
Post by mindovermatter on Jan 21, 2016 9:53:34 GMT -5
Boy, this ground breaking news makes me want to...
|
|
|
Post by mindovermatter on Jan 21, 2016 9:50:15 GMT -5
not even one statement from Receptor life? the company just formed for crying out loud. Give them some time to find a PR person, jeez! HA!
|
|
|
Post by mindovermatter on Jan 21, 2016 9:38:25 GMT -5
Just wonder who the CEO (or management team) is of Receptor Life Sciences. No one. It's the first fully automated biopharma run by droids.
|
|
|
Post by mindovermatter on Jan 21, 2016 9:30:46 GMT -5
Announcement of NDA submittals to the FDA will generate more buzz.
BTW, there are lots of nano-technology biotech development companies in Seattle. In what time frame where you thinking those NDA will happen? 1 year? I wouldn't think they'll be any time soon.
|
|
|
Post by mindovermatter on Jan 21, 2016 9:20:13 GMT -5
"Multiple inhaled therapeutic projects". Does not mention any "upfront" payments only potential milestone payments. And a very low royalty. I hope they didn't just transfer the bulk of potential for technosphere to a small new startup. Maybe it's a secret side project spun off from Sanofi! LOL One thing for sure is that it looks like we are back to silence from Mannkind with this "deal."
|
|
|
Post by mindovermatter on Jan 21, 2016 9:15:45 GMT -5
Absolute MEH. From a technical perspective this keeps MannKind over $1 PPS probably with no climb. The moment another large cap (ala Sanofi) Corporation shows interest it's off to the races. don't be so sure this news is going take MNKD over $1. Receptor life is a start up and I can't find squat about the company.
|
|
|
Post by mindovermatter on Jan 21, 2016 9:14:02 GMT -5
I am not so sure the market is going to be satisfied when it realizes there is no up front money and not much is known about Receptor Life. Its website is just one page with a notification button. That's it. Talk about transparency. Receptor life has no transparency. Hopefully Matt can elaborate a bit more who this company is. Maybe it has Gates foundation funding but that's a guess.
|
|
|
Post by mindovermatter on Jan 20, 2016 14:07:48 GMT -5
Should we be concerned of De-listing? I am long, just curious. I know they will have time but if they can't get the PPS up over the course of the year, this could become a concern or would they just do a reverse split? No, nothing to be worried about YET. Besides, the shorts won't let it get delisted. They are having too much fun shorting it. They'll have a much harder time shorting it if it gets delisted.
|
|
|
Post by mindovermatter on Jan 20, 2016 11:16:11 GMT -5
ive emailed him a couple times over the last 3 weeks with no response. the content wasn't "bashing" or long winded either, just a couple simple questions. Did you seriously think the guy would answer now that he is the CEO and trying to keep USS MANNKIND from sinking?
|
|
|
Post by mindovermatter on Jan 19, 2016 8:01:40 GMT -5
Re-establish the contact with those 6000 patients in clinical trials during the past 10 years. Help them to get insurance coverage and invite them (those qualified per label) to participate in Real Time Diabetic Management program, if any and share results with Afrezza Advocate Council. Get the momentum back before new pricing policy is introduced for further reinforcement of building up market share. Many of those in the clinical trials were not in the United States.
|
|